Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

U.S. stock markets have been enduring severe volatility over the past month. Wall Street’s recent turmoil is broad-based. The ...

JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...

A third of the Global Fund for HIV, TB and Malaria’s money comes from the United States. The other contributions come from other wealthy governments and philanthropic organisations. So, what happens ...

Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...